

Invasive Cervical Cancer

Type(s) of Surgery(ies)
in 2001?

In Search of Clinical Pathways: Illumination or Illusion

A National Cervical Cancer Survey

R. Boronow

Gynecologic Oncology 2000: 79, 143-144

Surgical Management of Cervical Cancer in the United States

- A -

32 directors of training
programs for
gynecologic oncology

Approved by ACOG

- B -

22 non university
gynecologic
oncologists

Members of ACOG

Stade Ia1 (<3mm)

- A -

- B -

Conization only	28%
Vaginal Hyst	38%
TAH	20%
LAVH	9%

Conization only	22%
Vaginal Hyst	49%
TAH	22%
LAVH	7%

Stade Ia2 (3-5mm)

- A -

Conization only	3%
Vaginal Hyst	12%
TAH	12%
LAVH	6%
Wertheim	61%
RxTTT only	6%

- B -

Conization only	5%
Vaginal Hyst	5%
TAH	5%
LAVH	5%
Wertheim	80%

Stade Ib1

- A -

Wertheim	89%
Schauta	2%
RxTTT	9%

- B -

Wertheim	96%
Rx TTT	4%

Stade Ib2

- A -

- B -

Wertheim 72%

Wertheim 68%

Rxttt 28%

Rx TTT 32%

(+/- chemo ?)

Stade Ib2

Postradiation Conservative Hyst

- A -

- B -

No	30%
Routine use	26%
Selective use	44%

No	18%
Routine use	23%
Selective use	59%

Stade IIa

- A -

Wertheim	57%
Rx TTT	43%

- B -

Wertheim	77%
Rx TTT	23%

Stade IIb

- A -

- B -

Rx TTT 97%

Wertheim 3%

Rx TTT 95%

Wertheim 5%

Neoadjuvant Chemotherapy

- A -

- B -

Routine (bulky) 6%

Selective 45%

No 49%

Likely to become standard
therapy 28%

Routine (bulky) 5%

Selective 33%

No 62%


Likely to become standard
therapy 40%

Conclusion

Lack of standard practice

→ Surgery = individualized

Evidence Based Medicine: Yes But



Multidisciplinary , personal training, experience & conviction